Účinky Lactobacillus Plantarum PS128 u dětí s ASD
Účinky Lactobacillus Plantarum PS128 u dětí s poruchou autistického spektra
Autism spectrum disorder (ASD) is a neurodevelopmental disorder that can cause significant social, communication and behavioral deficits. Probiotics are regarded as active microorganisms. With sufficient amounts, probiotics can regulate intestinal flora, intestinal permeability, inflammation and antioxidant reactions in the body. These reactions may further promote health, regulate metabolic disease progression and prevent complications. Lactobacillus plantarum PS128 (PS128) was reported to be a psychobiotic in several animal and human studies which modulated the levels of neurotransmitters in different brain areas. This study is to evaluate whether the consumption of PS128 can improve the symptoms of patients with ASD. The current randomized, placebo-controlled trial was conducted to investigate the psychophysiological effects of PS128 in school children with ASD.
Přehled studie
Postavení
Postavení
Podmínky
Podmínky
Intervence / Léčba
Intervence / Léčba
Typ studie
Typ studie
Zápis (Aktuální)
Zápis
Fáze
Fáze
- Nelze použít
Kontakty a umístění
Studijní místa
-
-
-
Taoyuan, Tchaj-wan
- Chang Gung Memorial Hospital
-
-
Kritéria účasti
Kritéria způsobilosti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- (1) Age 7 to 12 years old.
- (2) PS128 group and placebo group: Children with autism spectrum disorder, confirmed by Autism Diagnostic Observation Schedule.
- (3) Normal control group: Children without autism spectrum disorder.
Exclusion Criteria:
- (1) Receiving antibiotics within one month.
- (2) Probiotics used in powder, capsule, or tablet in two weeks (except for Yogurt, Yogurt, Yakult and other related foods).
- (3) Patients with hepatobiliary gastrointestinal tract who have undergone surgery (except for hernia surgery and appendectomy)
- (4) Those with special diets (gluten-free, casein-free, high-protein, and ketogenic diet).
- (5) Those with a history of cancer.
- (6) Those who are allergic to lactic acid bacteria.
- (7) Not eligible judged by PI
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Jiný
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Čtyřnásobek
Počet zbraní
Zbraně a zásahy
Skupina účastníků / ArmSkupina účastníků / Arm |
Intervence / LéčbaIntervence / Léčba |
|---|---|
|
Experimentální: PS128
Subjects will take PS128 capsules every day (2 capsules/day, once) for 12 weeks. |
Each PS128 capsule contained >3 × 10^10 colony forming units (CFU) with microcrystalline cellulose and weights 425 ± 25 mg. |
|
Komparátor placeba: Placebo
Subjects will take placebo capsules every day (2 capsules/day, once) for 12 weeks. |
The placebo capsules only contained 425 ± 25 mg microcrystalline cellulose. |
|
Žádný zásah: Normal control
Normal control group are enrolled by invitation from the age and gender matched healthy children. |
Co je měření studie?
Primární výstupní opatření
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Changes of Total Scores of Social Responsiveness Scale
Časové okno: Baseline, Week 12 and Week 16
|
Social Responsiveness Scale can measure the autism clinical severity with the range from 65-260. The lower scores stand for better social responsiveness. |
Baseline, Week 12 and Week 16
|
Sekundární výstupní opatření
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Changes of Total Scores of Repetitive Behavior Scale-Revised
Časové okno: Baseline, Week 12 and Week 16
|
Repetitive Behavior Scale-Revised is a questionnaire that focuses on repetitive behavior. The score ranges from 0-129. The lower scores stand for lower repetitive behavior. |
Baseline, Week 12 and Week 16
|
|
Changes of Total Scores of Child Behavior Checklist
Časové okno: Baseline, Week 12 and Week 16
|
Child Behavior Checklist is a parents' report questionnaire for behavioral and emotional problems. The score ranges from 0-240. The lower scores stand for better behavioral and emotional regulation. |
Baseline, Week 12 and Week 16
|
|
Changes of Total Scores of Adaptive Behavior Assessment System
Časové okno: Baseline, week 12 and Week 16
|
Adaptive Behavior Assessment System is a parents' report questionnaire for adaptive behavior. The score ranges from 9-171. The higher scores stand for better adaptive behavior. |
Baseline, week 12 and Week 16
|
|
Changes in Accuracy of Frith-Happe Animation
Časové okno: Baseline, Week 12 and Week 16
|
A quick and objective test of Theory of Mind. 8 questions in total, the more correct questions stand for better Social Cognition. |
Baseline, Week 12 and Week 16
|
|
Changes in Accuracy of Eyes Task
Časové okno: Baseline, Week 12 and Week 16
|
An advanced test for Theory of Mind. 43 questions in total, the more correct questions stand for better social skills. |
Baseline, Week 12 and Week 16
|
|
Changes of Total Scores of Aberrant Behavior Checklist
Časové okno: Baseline, Week 12 and Week 16
|
Aberrant Behavior Checklist is a parents' report questionnaire for aberrant behavior. The score ranges from 0-174. The lower scores stand for less aberrant behavior. |
Baseline, Week 12 and Week 16
|
|
Changes of Total Scores of Emotional Dysregulation Inventory
Časové okno: Baseline, Week 12 and Week 16
|
Emotional Dysregulation Inventory is a parents' report questionnaire for emotional dysregulation. The score ranges from 0-120. The lower scores stand for better emotional regulation. |
Baseline, Week 12 and Week 16
|
|
Changes of Total Scores of Parenting Stress Index, Fourth Editon
Časové okno: Baseline, Week 12 and Week 16
|
Parenting Stress Index is a parents' report questionnaire for parenting stress. The score ranges from 0-180. The lower scores stand for lower parenting stress. |
Baseline, Week 12 and Week 16
|
|
Assessment of Clinical Global Impression-Severity of Illness
Časové okno: Week 12 and Week 16
|
The Clinical Global Impression (CGI) is a clinician rated measure of illness severity, improvement, and efficacy of treatment. The CGI-I is a 7 point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention. The score ranges from 1-7. CGI Improvement scale: 1=very much improved; 2=Much improved; 3=Minimally improved; 4=No change; 5=Minimally worse; 6=Much worse; 7=Very much worse. |
Week 12 and Week 16
|
|
Assessment of Patient Global Impression of Change
Časové okno: Week 12 and Week 16
|
The self-report measure Patient Global Impression of Change (PGIC) reflects a patient's belief about the efficacy of treatment. PGIC is a 7 point scale depicting a patient's rating of overall improvement. The score ranges from 1-7. Patients rate their change as "1=very much improved ," "2=much improved," "3=minimally improved," "4=no change," "5=minimally worse," "6=much worse," or "7=very much worse)." |
Week 12 and Week 16
|
|
Gut Microbiota-Relative Abundance of Bifidobacterium Faecale
Časové okno: Baseline and Week 12
|
Collect the DNA of fecal flora to test the diversity and abundance of gut microbiota as well as short chain fatty acids in Stool samples. The 16S rRNA gene amplicons will be prepared following the Illumina protocol for preparing the 16S metagenomic sequencing library. Values represent percentages and range from 0 to 100%, with higher values indicating a higher relative abundance of the target bacterium in the gut microbiota |
Baseline and Week 12
|
|
MRI T1
Časové okno: Baseline and Week 12
|
Brain structural volumes (cm²). The advanced processing and analysis of the MRI data have been outsourced to an external core facility. Due to resource scheduling and the prolonged timeline required for specialized image preprocessing, the data analysis is currently in progress and has not yet been finalized. Therefore, quantifiable results are unavailable for summary in the data table at this time. |
Baseline and Week 12
|
|
Functional MRI (Resting-state/Biological Motion Task) - BOLD Signal
Časové okno: Baseline and Week 12
|
Blood-oxygen-level-dependent (BOLD) signal is a measurement used in fMRI, which reflects the neural activity. The advanced processing and analysis of the MRI data have been outsourced to an external core facility. Due to resource scheduling and the prolonged timeline required for specialized image preprocessing, the data analysis is currently in progress and has not yet been finalized. Therefore, quantifiable results are unavailable for summary in the data table at this time. |
Baseline and Week 12
|
|
Diffusion Tensor Imaging (DTI) - FA
Časové okno: Baseline and Week 12
|
Fractional anisotropy (FA) is a measurement used in DTI, which reflects the movement of water molecules. FA ranges from 0 to 1, the higher FA value may represent more intact axons. The advanced processing and analysis of the MRI data have been outsourced to an external core facility. Due to resource scheduling and the prolonged timeline required for specialized image preprocessing, the data analysis is currently in progress and has not yet been finalized. Therefore, quantifiable results are unavailable for summary in the data table at this time. |
Baseline and Week 12
|
|
Safety Assessment - Albumin
Časové okno: Baseline and Week 12
|
Safety is assessed function of liver and kidney such as albumin (3.5-5.4 g/dl). |
Baseline and Week 12
|
|
Safety Assessment - Total Protein
Časové okno: Baseline and Week 12
|
Safety is assessed function of liver and kidney such as total protein (6.4-8.3 g/dl). |
Baseline and Week 12
|
|
Safety Assessment - ALP
Časové okno: Baseline and Week 12
|
Safety is assessed function of liver and kidney such as ALP (135-320 U/L). |
Baseline and Week 12
|
|
Safety Assessment - Total Bilirubin
Časové okno: Baseline and Week 12
|
Safety is assessed function of liver and kidney such as total bilirubin (0.3-1.2 mg/dl). |
Baseline and Week 12
|
|
Safety Assessment - T-Cholesterol
Časové okno: Baseline and Week 12
|
Safety is assessed function of liver and kidney such as T-Cholesterol (<170 mg/dL). |
Baseline and Week 12
|
|
Safety Assessment - Uric Acid
Časové okno: Baseline and Week 12
|
Safety is assessed function of liver and kidney such as uric acid (<7.0 mg/dl). |
Baseline and Week 12
|
|
Safety Assessment - BUN
Časové okno: Baseline and Week 12
|
Safety is assessed function of liver and kidney such as BUN (7-25 mg/dl). |
Baseline and Week 12
|
|
Safety Assessment - Creatinine
Časové okno: Baseline and Week 12
|
Safety is assessed function of liver and kidney such as creatinine (0.2-1.0 mg/dl). |
Baseline and Week 12
|
|
Safety Assessment - AST
Časové okno: Baseline and Week 12
|
Safety is assessed function of liver and kidney such as AST (13-40 U/L). |
Baseline and Week 12
|
|
Safety Assessment - ALT
Časové okno: Baseline and Week 12
|
Safety is assessed function of liver and kidney such as ALT (7-40 U/L). |
Baseline and Week 12
|
|
Change in Levels of Exploratory Blood-based Biomarkers for Inflammatory Changes - MPO
Časové okno: Baseline and Week 12
|
Inflammatory is assessed via a composite measure of circulating cytokines - MPO (ng/mL) |
Baseline and Week 12
|
|
Change in Levels of Exploratory Blood-based Biomarkers for Inflammatory Changes - IL-1β
Časové okno: Baseline and Week 12
|
Inflammatory is assessed via a composite measure of circulating cytokines - IL-1β (pg/mL) |
Baseline and Week 12
|
|
Change in Levels of Exploratory Blood-based Biomarkers for Inflammatory Changes - TGF-β1
Časové okno: Baseline and Week 12
|
Inflammatory is assessed via a composite measure of circulating cytokines - TGF-β1 (pg/mL) |
Baseline and Week 12
|
|
Change in Levels of Exploratory Blood-based Biomarkers for Inflammatory Changes - Eotaxin
Časové okno: Baseline and Week 12
|
Inflammatory is assessed via a composite measure of circulating cytokines - Eotaxin (pg/mL) |
Baseline and Week 12
|
|
Change in Levels of Exploratory Blood-based Biomarkers for Inflammatory Changes - IL-6
Časové okno: Baseline and Week 12
|
Inflammatory is assessed via a composite measure of circulating cytokines - IL-6 (ng/mL) |
Baseline and Week 12
|
|
Change in Levels of Exploratory Blood-based Biomarkers for Oxidative Stress Changes - Serotonin
Časové okno: Baseline and Week 12
|
Oxidative stress is assessed via Serotonin (ng/mL). |
Baseline and Week 12
|
|
Change in Levels of Exploratory Blood-based Biomarkers for Oxidative Stress Changes - GABA
Časové okno: Baseline and Week 12
|
Oxidative stress is assessed via GABA (μmol/L). |
Baseline and Week 12
|
|
Change in Levels of Exploratory Blood-based Biomarkers for Oxidative Stress Changes - Cortisol
Časové okno: Baseline and Week 12
|
Oxidative stress is assessed via Cortisol (6-10am 4.82-19.5, 4-8pm 2.47-11.9, μg/dl). |
Baseline and Week 12
|
|
Gut Microbiota-Relative Abundance of Lactiplantibacillus Plantarum
Časové okno: Baseline and Week 12
|
Collect the DNA of fecal flora to test the diversity and abundance of gut microbiota as well as short chain fatty acids in Stool samples. The 16S rRNA gene amplicons will be prepared following the Illumina protocol for preparing the 16S metagenomic sequencing library. Values represent percentages and range from 0 to 100%, with higher values indicating a higher relative abundance of the target bacterium in the gut microbiota. |
Baseline and Week 12
|
Spolupracovníci a vyšetřovatelé
Sponzor
Sponzor
Spolupracovníci
Spolupracovníci
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Začátek studia
Primární dokončení (Aktuální)
Primární dokončení
Dokončení studie (Aktuální)
Dokončení studie
Termíny zápisu do studia
První předloženo
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
První zveřejněno
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Poslední zveřejněná aktualizace
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
Další identifikační čísla studie
Další identifikační čísla studie
- 202101416A3
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .